Antibiotics

Whole Genome Sequencing Market Global Industry Forecast Report 2018-2028, Featuring Profiles of Illumina, Agilent Technologies, 10 x Genomics, BGI, Oxford Nanopore, Nebula Genomics & Veritas Genetics

Retrieved on: 
Wednesday, January 31, 2024
Cloud, Volcanic explosivity index, Whole genome sequencing, Growth, Microbiology, Workflow, WES, Genomics, Research, AI, DNA, Bacteria, Government, Gene, Mutation, Diagnosis, Microorganism, Exon, Competition, Exome sequencing, Sequence, Next Generation, NGS, Cloud computing, Cancer, Genome, Infection, Antibiotics

DUBLIN, Jan. 31, 2024 /PRNewswire/ -- The "Whole Genome Sequencing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 31, 2024 /PRNewswire/ -- The "Whole Genome Sequencing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Whole Genome Sequencing Market is expected to grow with an impressive CAGR in the forecast period 2024-2028.
  • Increasing technological advancement in NGS instruments and update in technology utilized in Sequencing techniques are adding to further drive the sequencing market growth in the forecast period.
  • In this report, Whole Genome Sequencing Market has been segmented into the following categories:

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis

Retrieved on: 
Wednesday, January 31, 2024
Streptomyces, Fungal infection, Investigational New Drug, Venous stasis, Nail disease, Prevalence, IND, HDAC, Dermatophytosis, FDA, Ciclopirox, Onycholysis, Food, Vanda, Onychomycosis, Fungus, Antibiotics

WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.

Key Points: 
  • WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.
  • Onychomycosis, or tinea unguium, is a fungal infection of the nail.
  • Onychomycosis can result in discoloration of the nail, onycholysis (nail separation from the nail bed), and nail plate thickening.
  • There have not been any new onychomycosis treatments approved by the FDA since 2014.4
    Centers for Disease Control and Prevention.

The United States Patent Office Grants New Patent for Aurora Spine’s Translucent GhostTube™ Surgical Operating Tube

Retrieved on: 
Monday, January 29, 2024
ASG, TFX, Silo, Patent, United, Health, Antibiotics

CARLSBAD, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the issuance of its United States Patent No: 11,832,853 entitled “Hybrid Radiolucent Surgical Operating Tube”.

Key Points: 
  • CARLSBAD, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the issuance of its United States Patent No: 11,832,853 entitled “Hybrid Radiolucent Surgical Operating Tube”.
  • Aurora Spine’s Ghost Tube™ was designed to provide superior anchoring with a translucent thermoplastic body and non-slipping titanium anchors to assure that minimally invasive surgical access will stay stationary to support surgical preparation tools without blocking x-ray visualization during surgery.
  • "Aurora Spine has created several disruptive technologies in the past 12 years”, said Trent Northcutt, President & CEO of Aurora Spine. "
  • Aurora will continue being disruptive and innovative by looking at ways to efficiently deliver our products and create and improve new treatment options to improve patient care and overall patient outcomes.”

QIAGEN announces partnership with Penn State University to advance microbiome sciences

Retrieved on: 
Thursday, January 25, 2024
Senior, Student, Chitin, NGS, Research, Microbiome, Arthropod, Animal, Health, RNA, Partnership, Joint, Spider, Faculty, Genetics, Pennsylvania State University, Skeleton, Real-time, Environment, Bacteria, Arbovirus, Human, Reproduction, Entomology, Dengue fever, State College, Pennsylvania, Laboratory, Zika virus, QIAGEN, MITES, Virus, Organization, Wolbachia, Plant, PCR, Automation, Ecology, Education, QGEN, Nested polymerase chain reaction, Fungus, Antibiotics

Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.

Key Points: 
  • Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.
  • In doing so, this new partnership will provide QIAGEN with a site to support the development of new products as a testing center.
  • This includes an internship program for graduate students from Penn State at QIAGEN laboratories at the European operational headquarters in Hilden, Germany, and helps them prepare for careers in the biotechnology industry.
  • “Additionally, it will foster relationships with the microbiome research community and enable us to better develop new products for microbiome research based on direct customer feedback.”
    Seth Bordenstein, Director of the One Health Microbiome Center, Professor of Biology and Entomology, and Huck Endowed Chair in the Microbiome Sciences, at Penn State said: “The ‘One Health’ vision shared by QIAGEN and Penn State University is critical for microbiome research.

Genome Insight Receives College of American Pathologists Accreditation for Reliable Whole Genome Sequencing

Retrieved on: 
Monday, January 29, 2024
Hospitals, Genetics, Health Technology, Practice Management, Biotechnology, Other Health, Health, General Health, Oncology, Physician, Insight, Therapy, CAP, Whole genome sequencing, Patient, College, Neoplasm, Medicine, Accreditation, Antibiotics

Genome Insight, a clinical laboratory, is proud to announce its accreditation by the College of American Pathologists (CAP) for its whole genome sequencing services.

Key Points: 
  • Genome Insight, a clinical laboratory, is proud to announce its accreditation by the College of American Pathologists (CAP) for its whole genome sequencing services.
  • The CAP accreditation, effective January 2024, solidifies Genome Insight's status as a trusted provider of high quality and reliable genomic services.
  • Since the opening of the laboratory in San Diego in September 2022, Genome Insight has been dedicated to advancing precision medicine through the comprehensive analysis of tumor and normal samples using whole genome sequencing.
  • Stephanie Ferguson, Chief Clinical Operations Officer of Genome Insight, Inc., emphasizes the importance of whole genome sequencing in advancing precision medicine.

Eurofins Genomics Opens New Seattle Laboratory for Express Oxford Nanopore Sequencing

Retrieved on: 
Wednesday, January 24, 2024
Genomics, Oxford Nanopore Technologies, Genetics, Structural system, Antibiotics

SEATTLE, Jan. 24, 2024 /PRNewswire/ -- Eurofins Genomics, a global leader in sequencing services, announces the opening of a new, certified sequencing lab in Bothell, Washington, serving the greater Seattle area.

Key Points: 
  • SEATTLE, Jan. 24, 2024 /PRNewswire/ -- Eurofins Genomics, a global leader in sequencing services, announces the opening of a new, certified sequencing lab in Bothell, Washington, serving the greater Seattle area.
  • The facility leverages the Oxford Nanopore's sequencing platform and its local proximity to deliver results within 12 hours from sample pickup.
  • The company has already lined up 30 partner labs in Seattle and conducting daily sample pickup and sequencing for the biotech hub.
  • "Eurofins Genomics is proud to introduce our Seattle lab, where groundbreaking advancements in whole plasmid sequencing are set to transform the landscape of genetic research," said Sumit Gupta, President at Eurofins Genomics.

PRECISIO BIOTIX THERAPEUTICS EXPANDS THE US MANAGEMENT TEAM WITH THE HIRING OF DR. RAYMOND SCHUCH

Retrieved on: 
Tuesday, January 23, 2024
Genetically modified bacteria, Bacteria, Government, Lung, Engineering, Infection, AMR, Enzyme, AI, Lysin, Health, Antibiotics

DOVER, Del., Jan. 23, 2024 /PRNewswire/ -- Precisio Biotix Therapeutics ("Precisio") today announced the hiring of Dr. Raymond (Ray) Schuch as Vice President, Director of US Operations.

Key Points: 
  • The announcement by Mark Engel, the Company's Chairman and CEO, signifies a greater commitment to the US market
    DOVER, Del., Jan. 23, 2024 /PRNewswire/ -- Precisio Biotix Therapeutics ("Precisio") today announced the hiring of Dr. Raymond (Ray) Schuch as Vice President, Director of US Operations.
  • Precisio creates novel lower cost precision biological antibacterials with a focus on lung and skin infections.
  • Mark stated "We are delighted to welcome Ray to our team since he is one of the strongest scientists globally in the lysin field.
  • Their notable commitment to bringing such precision antimicrobials into clinical use was a driving factor in my decision to join Precisio, as was the opportunity to work with such a dynamic and successful team."

Next-gen Sequencing and Genomic Analysis Advancements Report 2024 - Enabling Precision Medicine through High-precision Sequencing Approaches

Retrieved on: 
Thursday, January 18, 2024
NGS, Biology, Research, Whole genome sequencing, DNA, RNA, Miniaturization, Single-nucleotide polymorphism, Drug discovery, Sequence, B cell, Drug development, Nanopore sequencing, Genome, Automation, Antibiotics

DUBLIN, Jan. 18, 2024 /PRNewswire/ -- The "Advancements in Next-gen Sequencing and Genomic Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 18, 2024 /PRNewswire/ -- The "Advancements in Next-gen Sequencing and Genomic Analysis" report has been added to ResearchAndMarkets.com's offering.
  • From Sanger sequencing to next-generation sequencing, technologies and chemistries have improved/advanced to reduce costs and ensure faster timelines.
  • Developments in NGS chemistries such as single-molecule real-time sequencing, sequencing by synthesis, nanopore sequencing, ion and semiconductor technology, in addition to miniaturization of sequencing instrumentation and automation of NGS, boost the adoption of NGS across biological labs.
  • Technological advancement of AI-/ML-powered platforms for analyzing sequencing data is helping analyze and interpret large volumes of sequencing data within hours.

Complete Genomics and Gencove Announce agreement at Plant and Animal Genome Conference (PAG 31) to offer a bundled solution for low-pass whole genome sequencing

Retrieved on: 
Tuesday, January 16, 2024
Entrepreneurship, Research, SAN, DNA, Partnership, Whole genome sequencing, GWAS, Complete Genomics, Genomics, Genome, Antibiotics

The partnership will combine Gencove's platform for data analytics and management with Complete Genomics' sequencing products and automation capabilities via high-throughput nucleic acid extraction, automated library preparation on its DNBSEQ-T7RS* and DNBSEQ-T20X2RS* sequencers.

Key Points: 
  • The partnership will combine Gencove's platform for data analytics and management with Complete Genomics' sequencing products and automation capabilities via high-throughput nucleic acid extraction, automated library preparation on its DNBSEQ-T7RS* and DNBSEQ-T20X2RS* sequencers.
  • "While low-pass whole genome sequencing has long been touted as an advanced method for everything from GWAS analysis to genotyping for molecular breeding, its potential hasn't been fully realized.
  • "Through this partnership with Complete Genomics, we're enabling higher throughput results at a lower cost per sample, making more affordable sequencing accessible to more researchers," said Joseph Pickrell, Ph.D., co-founder, and CEO of Gencove.
  • "It will provide the kind of comprehensive genome coverage that leads to the discovery of novel variants."

New antibiotic zosurabalpin shows promise against drug-resistant bacteria – an expert explains how it works

Retrieved on: 
Friday, January 5, 2024
World, Cell death, Infection, Carbapenem, Roche, Crab, Hospital, Mouse, Human, News, Clinical trial, Cell wall, Acinetobacter baumannii, Animal, System, World Health Organization, Toxicity, Patient, Bacteria, Sepsis, Antibiotics

Researchers have identified an entirely new class of antibiotic that can kill bacteria that are resistant to most current drugs.

Key Points: 
  • Researchers have identified an entirely new class of antibiotic that can kill bacteria that are resistant to most current drugs.
  • It is responsible for around 20% of infections in places like hospitals, care homes or other similar healthcare settings.
  • Antibiotics commonly work by crossing the cell wall that surrounds infectious bacteria to reach the vital machinery inside.
  • Crab is a clinical challenge as it has a double-layered cell wall, a feature that microbiologists describe as “gram negative”.

Zosurabalpin

  • Researchers tested zosurabalpin against more than 100 Crab samples from patients suffering from the infection.
  • The research team, found that zosurabalpin was able to kill all of these bacterial strains.
  • Zosurabalpin works by blocking a molecular machine called LptB2FGC that transports the lipopolysaccharide toxin from the inside barrier to the outside one.
  • The bad news is that zosurabalpin will only kill Crab infections and not those caused by other types of bacteria.
  • Zosurabalpin is now in phase 1 clinical trial for use in patients infected with Crab.
  • This early testing in humans will help the company developing the drug, Roche, to work out any side effects of the drugs as well as potential toxicity.


Jonathan Cox receives research funding from UKRI, charities and industry.

He is Co-Director of the Antibiotic Discovery Accelerator (ABX) Network